{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=3", "query": { "condition": "Colonic Cancer", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3054, "total_pages": 306, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T18:18:20.131Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00086931", "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2003-09", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2013-03-08", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086931" }, { "nct_id": "NCT03005002", "title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Carcinoma in the Liver", "MLH1 Gene Mutation", "MSH6 Gene Mutation", "PMS2 Gene Mutation", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 9, "start_date": "2017-06-28", "completion_date": "2019-11-26", "has_results": false, "last_update_posted_date": "2019-12-26", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005002" }, { "nct_id": "NCT06424522", "title": "A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Low Anterior Resection Syndrome", "Rectal Carcinoma" ], "interventions": [ { "name": "Dietary Fiber", "type": "DIETARY_SUPPLEMENT" }, { "name": "Enema Administration", "type": "PROCEDURE" }, { "name": "Loperamide Hydrochloride", "type": "DRUG" }, { "name": "Physical Therapy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2027-02-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06424522" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT05345054", "title": "The Deep South Surgical Equity Research Network: Addressing Socioecological Determinants of Health", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Inflammatory Bowel Diseases", "Diverticular Diseases", "Social Behavior" ], "interventions": [ { "name": "no intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-08-01", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 3, "location_summary": "Alexander City, Alabama • Demopolis, Alabama • Greenville, Alabama", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Demopolis", "state": "Alabama" }, { "city": "Greenville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05345054" }, { "nct_id": "NCT06184594", "title": "Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer Screening" ], "interventions": [ { "name": "eNav", "type": "OTHER" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 400, "start_date": "2024-01-24", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06184594" }, { "nct_id": "NCT04516083", "title": "Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer Gene Mutation", "Lynch Syndrome", "Endometrial Cancer", "Somatic Mutation" ], "interventions": [ { "name": "Mismatch repair instability somatic and germline testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "RWJ Barnabas Health at Jersey City Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 100, "start_date": "2019-12-21", "completion_date": "2021-06-30", "has_results": false, "last_update_posted_date": "2020-08-18", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Jersey City, New Jersey", "locations": [ { "city": "Jersey City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04516083" }, { "nct_id": "NCT07807956", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Biliary Tract Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2026-09-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807956" }, { "nct_id": "NCT00044863", "title": "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "Erbitux (Cetuximab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2002-08", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2011-02-23", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044863" }, { "nct_id": "NCT05692024", "title": "COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Coffee", "Gastrointestinal Microbiome", "Stenosis", "Fibrosis, Liver", "Ultrasound Elastography", "Proton Magnetic Resonance Spectroscopy" ], "interventions": [ { "name": "Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2024-03-21", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-22T18:18:20.131Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05692024" } ] }